Tentolouris Anastasios, Stafylidis Christos, Siafarikas Christos, Dimopoulou Maria N, Makrodimitri Sotiria, Bousi Stelios, Papalexis Petros, Damaskos Christos, Trakas Nikolaos, Sklapani Pagona, Spandidos Demetrios A, Georgakopoulou Vasiliki Epameinondas
First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Exp Ther Med. 2022 May;23(5):338. doi: 10.3892/etm.2022.11268. Epub 2022 Mar 21.
Sickle cell disease (SCD) is one of the most frequent and severe monogenic disorders, affecting millions of individuals worldwide. SCD represents a fatal hematological illness, characterized by veno-occlusive events and hemolytic anemia. Hemolytic anemia is caused by abnormal sickle-shaped erythrocytes, which induce parenchymal destruction and persistent organ damage, resulting in considerable morbidity and mortality. During the coronavirus disease 2019 (COVID-19) pandemic, patients with SCD were characterized as a 'high-risk' group due to their compromised immune system, caused by functional hyposplenism, as well as systemic vasculopathy. COVID-19 is characterized by endothelial damage and a procoagulant condition. The present study describes the clinical features, management and outcomes of 3 patients with SCD who were hospitalized due to COVID-19, who all had favorable outcomes despite the complications.
镰状细胞病（SCD）是最常见且严重的单基因疾病之一，影响着全球数百万人。SCD是一种致命的血液疾病，其特征为静脉闭塞性事件和溶血性贫血。溶血性贫血由异常的镰状红细胞引起，这些红细胞会导致实质破坏和持续性器官损伤，从而造成相当高的发病率和死亡率。在2019冠状病毒病（COVID-19）大流行期间，由于功能性脾功能减退以及系统性血管病变导致免疫系统受损，SCD患者被列为“高危”群体。COVID-19的特征是内皮损伤和促凝状态。本研究描述了3例因COVID-19住院的SCD患者的临床特征、治疗及结局，尽管出现了并发症，但所有患者均取得了良好的结局。
